Please enable Javascript
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Leah Sherwood
Articles by Leah Sherwood
Valeria Santini, MD, on Novel Drugs for Low-Risk MDS, Anemia
Valeria Santini, MD
Myelodysplastic Syndromes
|
October 24, 2024
At EHA 2024, Dr. Santini shares data on luspatercept and imetelstat in patients with MDS and anemia.
View More
Guillermo Garcia-Manero, MD, Shares Latest Luspatercept Findings for MDS, Anemia
Guillermo Garcia-Manero, MD
Myelodysplastic Syndromes
|
October 24, 2024
Dr. Garcia-Manero discusses the latest updates from the COMMANDS trial.
View More
Guillermo Garcia-Manero, MD, Shares Recent Progress in Low-Risk MDS
Melissa Badamo
Myelodysplastic Syndromes
|
September 26, 2024
Dr. Garcia-Manero discussed luspatercept, a first-in-class drug for patients with low-risk MDS and anemia.
View More
Get to Know ... Amy DeZern, MD
Leah Sherwood
Print
|
August 22, 2024
Dr. DeZern discusses how medicine has changed and shares some advice for early-career clinicians.
Read More
Thomas Martin, MD, Looks Forward to SOHO 2024
Melissa Badamo
Video Insights
|
July 24, 2024
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, in Houston, Texas.
View More
Lore Gruenbaum, PhD, Discusses the LLS Therapy Acceleration Program
Melissa Badamo
Video Insights
|
July 22, 2024
The foundation conducts partnerships with companies to provide funding to accelerate novel blood cancer therapies.
View More
Dr. Martin Highlights Recent Myeloma Research at EHA 2024
Melissa Badamo
Myeloma
|
July 24, 2024
Dr. Martin highlighted research in quadruplet therapy, CAR-T therapy, and bispecific T-cell engagers.
View More
Beat AML Trial to Expand into MDS Therapy
Melissa Badamo
Myelodysplastic Syndromes
|
July 18, 2024
The Beat AML trial has provided practice-changing insights and allows investigators to assess the potential of novel agents.
View More
Retrospective Study Asks Which BTK Inhibitor Has the Best Safety, Efficacy
Leah Sherwood
Meeting News
|
July 19, 2024
Acalabrutinib and zanubrutinib demonstrated better safety and efficacy outcomes when compared with ibrutinib in CLL/SLL.
Read More
How Are Erythropoiesis-Stimulating Agents Used in MDS Care Today?
Amer Zeidan, MBBS, MHS
The HemOnc Pulse Live
|
July 2, 2024
The expert panel discusses current issues in the use of ESAs within MDS management.
View More
How Is Luspatercept Being Used in Lower-Risk MDS Management?
Amer Zeidan, MBBS, MHS
The HemOnc Pulse Live
|
July 1, 2024
In a roundtable discussion, an expert panel discussed how approval of luspatercept has affected frontline MDS treatment.
View More
What Is the Impact of JAK2 Allele Burden in Patients With Myelofibrosis?
Melissa Badamo
Myelofibrosis
|
July 1, 2024
Julie Braish, MBBCh, discusses her study on JAK2 allele burden in myelofibrosis presented at ASCO 2024.
View More
Luspatercept ‘Preferred’ Therapy in ESA-Naive Patients With Lower-Risk MDS-Associated Anemia
Leah Sherwood
Myelodysplastic Syndromes
|
June 27, 2024
The authors reported clinically meaningful responses of luspatercept treatment from patients enrolled in the COMMANDS trial.
Read More
Guillermo Garcia-Manero, MD, Looks Ahead to SOHO 2024
Melissa Badamo
Video Insights
|
June 25, 2024
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, at the George R. Brown Convention Center in Houston, Texas.
View More
Tycel Phillips, MD, Shares Glofitamab Data in MCL
Tycel Phillips, MD
Mantle Cell Lymphoma
|
June 25, 2024
The 15-month PFS was approximately 33% for patients who were BTK exposed and over 50% for patients who were BTK naïve.
View More
How Do Clinicians Navigate the Two MDS Classification Systems?
Amer Zeidan, MBBS, MHS
The HemOnc Pulse Live
|
June 21, 2024
The expert panel describes how having two separate classification systems for MDS affects their clinical practices.
View More
How Do Clinicians Communicate With Patients About Lower-Risk MDS?
Amer Zeidan, MBBS, MHS
The HemOnc Pulse Live
|
August 29, 2024
The expert panel discusses how to explain to patients the range of MDS severities and approach lower-risk disease.
View More
How Is Molecular Testing Used in MDS Risk Stratification?
Amer Zeidan, MBBS, MHS
The HemOnc Pulse Live
|
June 17, 2024
The expert panel discusses molecular testing's current place in MDS evaluation and treatment decisions.
View More
Raajit Rampal, MD, PhD, on Bone Marrow Recovery in the MANIFEST-2 Trial
Leah Sherwood
Myelofibrosis
|
June 17, 2024
Dr. Rampal, of Memorial Sloan Kettering Cancer Center, discusses his abstract at the EHA 2024 Congress in Madrid, Spain.
View More
What Is the Benefit of Rituximab Maintenance in Patients With MCL?
Yucai Wang, MD, PhD
Mantle Cell Lymphoma
|
June 14, 2024
After five and a half years of follow-up, rituximab maintenance significantly improved survival outcomes.
View More
Load More